Multiple sclerosis affects an estimated

400,000 TO 1 MILLION AMERICANS
Source: World Health Organization and National MS Society
Research Addressing Questions That Matter
PCORI funds comparative clinical effectiveness research (CER) to determine which healthcare options work best for which patients, based on their needs and preferences. CER produces evidence that helps people make better-informed healthcare choices. 
PATIENT
STUDY SPOTLIGHTS
Comparative Effectiveness of Two
MS Drug
Two oral medications for MS, fingolimod and dimethyl fumarate, have been shown effective in reducing the rate of relapse in patients with the relapsing-remitting form of the disease. This project is the first head-tohead comparison of these medications' safety and effectiveness in staving off relapses. It is also the first study to consider patients' overall disease experience and quality of life as important outcomes. The study will include sites in the United States, Europe, Italy, and Israel. More information about this project may be found at www.pcori.org/Rossi016.
Building Capacity for Patient-Centered Research
PCORI is investing in people and infrastructure to support high-quality patient-centered research for years to come. PCORnet, the National Patient-Centered Clinical Research Network, will enable us to learn from the data and experiences of 100 million Americans. It is building capacity for research and other studies by supporting patient-driven networks and helping them connect with researchers who are studying similar topics, including multiple sclerosis.
PCORI has invested $2.3 million to develop iConquerMS, one of the patient-powered networks within PCORnet. It is helping to drive research that is led and informed by those living with MS. People can securely contribute their health information to iConquerMS and provide researchers with data they need to find answers. It has enrolled more than 3,000 patients with a goal of enrolling 20,000. It is endorsed by the National Multiple Sclerosis Society, the Multiple Sclerosis Foundation, the Multiple Sclerosis Association of America and the Multiple Sclerosis Coalition.
